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ABSTRACT
Purpose: Endotype in chronic rhinosinusitis (CRS) has been established in the last decade.
However, the exact immunologic profile of CRS still has controversy because it has a
considerable immunologic heterogeneity. Therefore, we investigated various inflammatory
mediators according to different nasal tissues in chronic rhinosinusitis and compared them
within the same subject.
Methods: We collected uncinate process mucosa (UP) and nasal polyp (NP) tissues from
controls, CRS without NP (CRSsNP) and CRS with NP (CRSwNP). Expression levels of 28
inflammatory mediators including T helper (Th) 1, Th2, Th17, proinflammatory cytokines
and remodeling markers were determined by multiplex immunoassay and were analyzed
using paired tests as well as principal component analysis (PCA) to investigate endotype in
each subtype of CRS.
Results: Signature inflammatory mediators are interleukin (IL)-5, C-C motif chemokine
ligand (CCL)-24, monocyte chemoattractant protein (MCP)-4, and vascular cell adhesion
molecule (VCAM)-1 in eosinophilic NP, whereas IL-17A, IL-1β, and matrix metallopeptidase
(MMP)-9 were detected as signature inflammatory markers in non-eosinophilic NP. Despite
differences in inflammatory cytokine profile between eosinophilic and non-eosinophilic NP,
the common upregulation of IL-5, CCL-11, IL-23, IL-2Rα, VCAM-1, MMP-3 and MMP-9 were
shown in NP compared to UP within the same subject. In the PCA, we observed that Th2
immune response was helpful in discriminating between nasal tissues in subtypes of CRS
and that there was a partial overlap between non-eosinophilic NP and eosinophilic NP in
terms of Th2 mediators.
Conclusions: Commonly upregulated mediators in NP were Th2-associated, compared with
UP regardless of CRS subtypes, whereas signature markers were distinct in each NP subtype.
These findings imply that Th2 inflammatory responses may play a role in the development of
NP regardless of CRSwNP subtypes.
Keywords: Cytokines; rhinitis; sinusitis; nasal polyp
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INTRODUCTION
Chronic rhinosinusitis (CRS) is a common chronic inflammatory disease of the nasal and
paranasal mucosa.1 It usually causes substantial impaired quality of life, reduced workplace
productivity, and is related to substantial direct and indirect economic cost.2,3 CRS is a
highly heterogeneous disease and currently defined as subgroups of patients based on nasal
endoscopic findings, either accompanied by nasal polyps (CRSwNP) or without nasal polyps
(CRSsNP).1 However, clinical phenotype dose not adequately reflect the pathophysiologic
diversity within patients with CRS.4-6 Evidence from several studies suggested that CRSsNP
is characterized by a predominant T helper (Th) 1 inflammatory response, whereas CRSwNP
is driven by a Th2 inflammation and increased eosinophilic infiltration.4-6 In addition,
within the same clinical phenotype, several studies have revealed the presence of different
immunologic endotypes.7-14 These studies showed that patients with CRSwNP in Asians
displayed a mixed T-cell profile with a non-eosinophilic inflammation pattern.10-14
Recent studies have shown regional differences in CRS endotypes. One study has
demonstrated that Th1/Th2/Th17 cytokine profile is diverse in terms of the immunologic
endotypes among CRS subjects in Europe, China, Japan and Australia.15 Another study also
revealed that second-generation Asian patients with CRSwNP living in the United States
had a lower percentage of eosinophilic NPs compared to other ethnic groups, probably
as a consequence of their genetic influence.16 Moreover, one cluster analysis study with
phenotype-free approach has identified that CRS patients have 10 distinct inflammatory
endotypes which are correlated with phenotype and that these endotypes comprise 4
clusters with low interleukin (IL)-5 and 6 clusters with moderate to high IL-5.8 To date,
some epithelial derived cytokines also have an important role in the development of CRS
according to its endotype.17-19 Furthermore, one recent study deomnstrated seven CRS
clusters with distinct endotypes and treatment outcomes.9 These studies indicate that CRS
shows remarkable heterogeneity at the molecular level and various treatment response.
However, the question is still unanswered whether CRS represents a serial clinical spectrum
disease (evolution from CRSsNP to CRSwNP) or manifest as 2 different diseases that develop
separately. To address this issue, a cohort study should be designed; however, it is difficult to
conduct a cohort study due to ethical problems. Although the present study was designed as a
cross-sectional study, we used the paired comparison of nasal tissues from uncinate process
mucosa (UP) and NP within the same CRSwNP patient to partially overcome the limitation of
cross-sectional study. Therefore, in this study, we investigate the differences in immunologic
profile among CRS subtypes and intend to seek the signature immunologic markers for the
development of NP.

MATERIALS AND METHODS
Patients and tissue samples
Sinonasal and polyp tissues were obtained from patients with bilateral CRS during routine
functional endoscopic sinus surgery. All subjects provided written informed consent for
study participation, and the study was approved by the internal review board of Seoul
National University Hospital, Boramae Medical Center. The diagnosis of CRS was based on
personal history, physical examination, nasal endoscopy and computed tomography findings
of the sinuses according to the 2012 European position paper on rhinosinusitis and nasal
https://e-aair.org
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Table 1. Demographic and clinical characteristics of patients
Parameters
Control (n = 9)
CRSsNP (n = 20)
NE-CRSwNP (n = 11) E-CRSwNP (n = 16) NE-CRSwNP (n = 15) E-CRSwNP (n = 21)
Tissue used
UP
UP
UP
UP
NP
NP
Male/female
14/8
12/8
11/0
14/2
13/2
17/4
Age (yr)
63 ± 13.75
52 ± 15.2
50 ± 28.5
44 ± 34.25
47 ± 24.5
50 ± 8
Atopy (%)
1 (11)
5 (25)
3 (27)
9 (56)
3 (20)
11 (52)
Asthma (%)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
Smoker (%)
1 (11)
7 (35)
7 (63)
7 (44)
7 (46)
9 (43)
Duration (mon)
N/A
7.5 ± 10.25
120 ± 204
90 ± 111
60 ± 120
90 ± 148
CT scores
N/A
7 ± 2.75
15 ± 4.5
14.5 ± 5
18 ± 6.5
14 ± 8
UP, uncinate process tissue; NP, nasal polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; E, eosinophilic; NE, non-eosinophilic; CRSwNP, chronic
rhinosinusitis with nasal polyps; CT, computed tomography.

polyps (EPOS) guidelines.1 Exclusion criteria were as follows: 1) younger than 18 years of age;
2) prior treatment with antibiotics, systemic or topical corticosteroids, or other immunemodulating drugs for 4 weeks before surgery; and 3) unilateral rhinosinusitis, antrochoanal
polyp, allergic fungal sinusitis, cystic fibrosis, or immotile ciliary disease. Control tissues
were obtained during other rhinologic surgeries, such as skull base, lacrimal duct or orbital
decompression surgery, from patients without any sinonasal diseases. UP tissue was obtained
from control subjects and those with CRSsNP or CRSwNP. NP tissue was also obtained
from CRSwNP patients. All samples were homogenized with a mechanical homogenizer at
1,000 rpm for 5 minutes on ice. After homogenization, the suspensions were centrifuged at
3,000 rpm for 10 minutes at 4ºC, and the supernatants were separated and stored at −80ºC
for further analysis of cytokines and other inflammatory mediators. The atopic status of
study subjects was evaluated using the ImmunoCAP® assay (Phadia, Uppsala, Sweden) to
detect immunoglobulin E (IgE) antibodies against 6 mixtures of common aeroallergens
(house dust mites, molds, trees, weeds and grass pollen, and animal dander). Subjects were
considered atopic if the allergen-specific IgE level was greater than 0.35 kU/L to any 1 or more
of the allergens. A diagnosis of asthma was based on the medical history and lung function
analysis, including methacholine challenge test by an allergist. In this study, CRSwNP were
classified as eosinophilic CRSwNP (E-CRSwNP) if eosinophils comprised more than 10%
of the inflammatory cell population and as non-eosinophilic CRSwNPs (NE-CRSwNP) if
eosinophils comprised less than 10% of the inflammatory cells.11,20 Additional information
and details of the subjects' characteristics are listed in Table 1.

Measurement of inflammatory mediators
The protein concentrations for tissue extracts were determined using the Pierce 660 nm
Protein Assay Kit (Thermo Scientific Inc., New York, NY, USA). All the protein levels in the
tissue homogenate were normalized to the concentration of total protein (mg/mL). Samples
were thawed at room temperature and vortexed to ensure well-mixed samples. In the present
study, multiplex cytokine analysis kits (IL-1α, IL-1β, IL-2Rα, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17A,
IL-22, IL-23, interferon [IFN]-γ, tumor necrosis factor [TNF]-α, C-C motif chemokine ligand
[CCL]-11, CCL-24, RANTES, CXCL-1, CXCL-2, CXCL-8, myeloperoxidase [MPO], monocyte
chemoattractant protein [MCP]-4, vascular cell adhesion molecule [VCAM]-1, intercellular
adhesion molecule [ICAM]-1, matrix metallopeptidase [MMP]-1, MMP-2, MMP-3, MMP-9,
tissue inhibitor of metalloproteinase [TIMP]-1 were obtained from R&D systems (Cat. No.
LMSAHM), and data were collected using Luminex 100 (Luminex, Austin, TX, USA). Data
analysis was performed using the MasterPlex QT version 2.0 (MiraiBio, Alameda, CA, USA).
Sensitivity of each cytokine is as follows: IL-1α (0.9 pg/mL), IL-1β (0.8 pg/mL), IL-2Rα (1.3 pg/mL),
IL-4 (9.3 pg/mL), IL-5 (0.5 pg/mL), IL-6 (1.7 pg/mL), IL-10 (1.6 pg/mL), IL-13 (32.4 pg/mL), IL-17A
(1.8 pg/mL), IL-22 (11.7 pg/mL), IL-23 (11.4 pg/mL), IL-33 (1.8 pg/mL), IFN-γ (0.4 pg/mL), TNF-α
https://e-aair.org
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(1.2 pg/mL), CCL-11 (14.6 pg/mL), CCL-24 (1.34 pg/mL), RANTES (1.8 pg/mL), CXCL-1 (5.3 pg/mL),
CXCL-2 (7.86 pg/mL), CXCL-8 (1.82 pg/mL), MPO (20.4 pg/mL), MCP-4 (0.42 pg/mL), VCAM-1
(238 pg/mL), ICAM-1 (87.9 pg/mL), MMP-1 (2.7 pg/mL), MMP-2 (108 pg/mL), MMP-3 (5.3 pg/mL),
MMP-9 (13.6 pg/mL) and TIMP-1 (3.42 pg/mL). All assays were run in duplicate according to the
manufacturers' protocol.

Statistical analysis
Statistical analyses were performed using IBM SPSS 21 (SPSS, Inc., Chicago, IL, USA) and
GraphPad Prism software 6.0 (GraphPad Software Inc, La Jolla, CA, USA). Descriptive statistics
were performed, and values are described as a median ± interquartile range. For comparisons
among multiple groups, the Kruskal-Wallis test was first used to establish the significant
difference and then, if the significance was found, the Mann-Whitney U test was secondarily
performed between 2 groups and Bonferroni correction was used to adjust the significance level
for each comparison. Specific differences between 2 groups were determined by the MannWhitney test. Correlations were assessed by Spearman rank. The significance level was set at
α value of 0.05. A multivariate analysis of multiplex or enzyme-linked immunosorbent assay
(ELISA) protein data was performed using principal component analysis (PCA) on correlation
matrices of protein levels of all measured mediators of inflammation.

RESULTS
Signature inflammatory markers in subtypes of chronic rhinosinusitis
To characterize the profile of cytokines and inflammatory mediators according to the
CRS phenotype, we performed ELISA and multiplex bead-based immunoassay for key
inflammatory mediators in UP tissues from controls, CRSsNP and CRSwNP, and in NP
tissues from CRSwNP (Tables 2 and 3).
NP tissues from NE-CRSwNP showed higher expression levels of Th2-associated mediators
(IL-4, IL-5, IL-13, CCL-11, CCL-24, MCP-4, and RANTES), Th17-associated mediators
(IL-17A, IL-23, CXCL-1, CXCL-2 and CXCL-8), IFN-γ as a Th1 cytokine, pro-inflammatory
cytokines (IL-1α, IL-1β, IL-2Rα and IL-6), and adhesion molecule (ICAM-1) than UP tissues
from controls. These results are consistent with those of previous reports demonstrating a
mixed inflammation pattern of NE-CRSwNP.11-13 In the analysis of remodeling markers, the
increased expression of MMP-1 and MMP-9 was observed in NP tissues from NE-CRSwNP,
whereas TIMP-1 was down-regulated. Among them, the signature inflammatory markers
which were at the highest level among all the groups in NE-CRSwNP were IL-17A, IL-1β,
and MMP-9. Interestingly, MMP-9 has been reported to be associated with neutrophilic
inflammation.21,22
Meanwhile, we found that the levels of Th2-associated mediators (IL-4, IL-5, IL-13, CCL-11,
CCL-2,4 and MCP-4), pro-inflammatory cytokines (IL-1α, IL-1β, IL-2Rα, and IL-6), adhesion
molecule (VCAM-1 and ICAM-1) and IL-23 were increased in NP tissues from E-CRSwNP,
compared with UP tissues from controls. These results were in accordance with those of
previous reports demonstrating Th2-deviated inflammation in E-CRSwNP.4-6 In the analysis
of remodeling markers, the increased expression of MMP-1, MMP-3, and MMP-9 was
observed in NP tissues from E-CRSwNP. Among them, the signature inflammatory markers
of E-CRSwNP are IL-5, CCL-11, MCP-4, and VCAM-1.

https://e-aair.org
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Table 2. The profile of inflammatory mediators in the subtype of chronic rhinosinusitis
Parameters (pg/mg)
Control (n = 9)
CRSsNP (n = 20)
NE-CRSwNP (n = 15)
E-CRSwNP (n = 21)
Tissue used
UP
UP
NP
NP
IL-4
12.26 (10.09–14.07)
21.47 (16.07–23.82)
19.43 (17.22–22.6)*
23.96 (19.91–27.6)*
IL-5
1.91 (1.86–2.04)
3.60 (2.85–6.95)*
3.186 (2.734–6.198)*
12.3 (3.441–34.14)*,†,‡
IL-13
29.99 (0–59.60)
55.6 (40.46–101.4)*
62.1 (49.83–91.5)*
67.61 (58.01–99.69)*
IL-17A
0.354 (0.264–0.662)
1.077 (0.5862–3.094)*
2.427 (1.124–4.18)*,†,‡
0.8769 (0.5223–2.584)
IL-2
18.26 (14.49–29.42)
28.19 (19.89–62.66)
49.87 (34.37–56.84)
41.46 (33.81–118.5)
IL-23
1.1 (0.00–3.21)
4.146 (2.631–12.18)*
47.02 (25.92–60.52)*,†
39.91 (18.8–58.81)*,†
IFN-γ
3 (0–7.286)
6.592 (4.271–12.03)
4.751 (3.852–6.03)*
3.982 (2.479–4.918)
TNF-α
1.18 (0.72–1.90)
1.286 (0.9666–3.298)
1.6 (1.079–2.628)
1.583 (1.117–2.593)
IL-10
0.34 (0.31–0.37)
0.4392 (0.3368–0.8086)
0.425 (0.3039–0.6192)
0.3455 (0.2597–0.4748)
CCL-11
7.8 (1.716–13.04)
22.47 (17.24–55.23)
47.34 (29.15–105.8)*,†
69.21 (33.81–111.85)*,†
*
CCL-24
53.13 (36.72–81.53)
171.5 (130.8–272)
282.2 (111.3–416.4)
1,046 (233.7–1,516)*,†,‡
MCP-4
4.33 (2.94–7.69)
12.35 (4.856–58.11)
21.08 (12.43–35.97)*
139.6 (33.36–376.6)*,†,‡
RANTES
402.2 (340.6–585.8)
1,498.0 (610.5–2,446.0)
1,016 (603.5–1,636)*
691.6 (454.4–1,177)
CXCL-1
293.7 (166–382.1)
732.9 (343.6–1,507)
1,649 (665.9–2,733)*
1,159 (602.8–3,641)
CXCL-2
14.97 (11.08–29.39)
31.01 (26.54–82.43)*
36.39 (24.8–54.03)*
33.19 (9.623–44.34)
CXCL-8
26.89 (19.14–46.71)
254.7 (76.76–373.4)
267.7 (120.7–14.8)*
138.6 (33.11–628.4)
MPO
23,020 (11,160–29,880)
42,423 (24,148–57,415)
29,320 (20,270–34,780)
14,020 (9,842–33,020)
IL-1α
0.094 (0–0.151)
0.2424 (0–0.591)
0.981 (0.4724–1.595)*,†
1.569 (0.6156–2.394)*,†
IL-1β
0.128 (0–1.656)
0.969 (0.2801–2.399)
3.903 (2.825–10.27)*,†,‡
1.097 (0–2.75)
IL-2Rα
19.07 (10.94–26.36)
19.54 (14.92–41.39)
60.84 (52.58–81.79)*,†
85.43 (63.29–92.5)*,†
IL-6
1.343 (0.2786–3.217)
2.793 (0.8654–5.854)
10.1 (2.982–22.6)*,†
13.29 (5.348–36.57)*,†
ICAM-1
44,431 (19,158–84,951)
107,961 (56,298–192,848)*
91,530 (62,390–137,100)*
88,780 (47,640–127,300)*
VCAM-1
6,326 (5,652–7,446)
7,045 (5,159–9,613)
7,622 (6,234–10,510)
11,910 (8,750–16,850)*,†,‡
Values in bold mean higher expression compared with controls.
UP, uncinate process tissue; NP, nasal polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; E, eosinophilic; NE, non-eosinophilic; CRSwNP, chronic
rhinosinusitis with nasal polyps; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; CCL, C-C motif chemokine ligand; MCP, monocyte chemoattractant
protein; MPO, myeloperoxidase; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule.
*The comparison between control vs. CRSsNP or NE-CRSwNP or E-CRSwNP; †the comparison between CRSsNP vs. NE-CRSwNP or E-CRSwNP; ‡the comparison
between NE-CRSwNP vs. E-CRSwNP.
Table 3. The profile of remodeling mediators in the subtype of chronic rhinosinusitis
Parameters (pg/mg)
Control (n = 9)
CRSsNP (n = 20)
NE-CRSwNP (n = 15)
E-CRSwNP (n = 21)
Tissue used
UP
UP
NP
NP
MMP-1
49.15 (29.51–84.14)
99.13 (43.49–105.5)
178.8.8 (105.2–244.4)*,†
320.7 (203.6–454.4)*,†
MMP-2
10,710 (7,338–15,860)
9,852 (6,192–18,340)
13,940 (12,150–15,570)
11,490 (8,440–14,290)
MMP-3
371.4 (240.2–574.8)
306.8 (249.3–428.5)
620 (478.3–945.2)
853.1 (609.6–1,200)*
MMP-9
543 (171.6–720.6)
650.8 (498.8–898.0)*
13,330 (4,818–28,210)*,†,‡
1,699 (966.3–7,847)*
TIMP-1
11,473 (10,645–11,915)
12,186 (7,733–15,251)
6,929 (5,854–8,338)*
11,280 (8,387–13,240)
M1T1
0.00291 (0.001948–0.00291)
0.003917 (0.0029–0.01063)
0.02681 (0.01152–0.03034)*,†
0.0272 (0.01989–0.04809)*,†
M2T1
1.381 (1.254–1.450)
1.486 (1.115–1.901)
1.98 (1.752–2.186)*,†,‡
1.054 (0.8–1.678)
M3T1
0.03827 (0.02044–0.06068)
0.02518 (0.01525–0.06858)
0.08902 (0.07041–0.1343)*
0.07475 (0.05746–0.1508)*
M9T1
0.04875 (0.01708–0.06818)
0.04312 (0.0112–0.1496)
1.741 (0.7074–3.566)*,†,‡
0.1567 (0.07116–1.034)*
Values in bold mean higher expression compared with controls.
UP, uncinate process tissue; NP, nasal polyps; CRSsNP, chronic rhinosinusitis without nasal polyps; E, eosinophilic; NE, non-eosinophilic; CRSwNP, chronic
rhinosinusitis with nasal polyps; MMP, matrix metalloproteinase; TIMP, tissue inhibitors of metalloproteinase; M1T1, ratio of MMP1 to TIMP1; M2T1, ratio of MMP2
to TIMP1; M3T1, ratio of MMP3 to TIMP1; M9T1, ratio of MMP1 to TIMP1.
*The comparison between control vs. CRSsNP or NE-CRSwNP or E-CRSwNP; †the comparison between CRSsNP vs. NE-CRSwNP or E-CRSwNP; ‡the comparison
between NE-CRSwNP vs. E-CRSwNP.

On the analysis of UP tissues from CRSsNP, Th2 cytokines (IL-5 and IL-13) and Th17associated mediators (IL-17A, IL-22, IL-23, CXCL-2, and ICAM-1) and MMP-9 were
significantly up-regulated, compared with controls. These results mean that CRSsNP is
characterized by mixed inflammation and their immunologic characteristics are similar to
those of NE-CRSwNP. However, there are no signature inflammatory markers in CRSsNP,
compared with UP or NP tissues of other subtypes of CRS (Supplementary Tables S1 and S2).

https://e-aair.org

https://doi.org/10.4168/aair.2019.11.2.201

205

Immunological Feature in Chronic Rhinosinusitis

The difference in inflammatory cytokine profiles between uncinate process
mucosa and NP tissues within the same subject according to the endotype of
chronic rhinosinusitis with NP
To evaluate the difference in cytokines, inflammatory mediators, and remodeling markers
related to the evolution of NPs, we compared levels of expression between UP and NP tissues
within the same patients (Tables 4 and 5). Although NP tissues from NE-CRSwNP and
E-CRSwNP showed different signature inflammatory profiles in Tables 2 and 3, both groups
showed common changes in several immunologic profiles on the comparison between UP and
NP tissues. We found that up-regulation of Th2-associated mediators (IL-5 and CCL-11), IL-23,
IL-2Rα, VCAM-1, and remodeling markers such as MMP-3, MMP-9 were observed in both NP
Table 4. Paired comparison of inflammatory mediators between UP and NP tissues within each endotype of CRSwNP
Parameters (pg/mg)
NE-CRSwNP (UP)
NE-CRSwNP (NP)
E-CRSwNP (UP)
E-CRSwNP (NP)
IL-4
14.04 (13–23)
18.17 (16.22–19.95)
20.12 (16.62–21.47)
24.28 (21.35–28.14)
IL-5
2.293 (1.408–2.708)
3.319 (2.846–6.027)*
2.879 (2.19–3.257)
12.07 (2.759–25.43)‡
IL-13
84 (39.31–138.4)
63.52 (41.89–90.3)
61.27 (32.33–91.62)
64.01 (56.02–97.15)
IL-17A
2.599 (1.142–5.508)
2.587 (1.622–4.81)
0.7004 (0.5851–1.585)
0.8769 (0.5656–3.302)
IL-22
52.11 (18.59–59.28)
50.82 (36.26–61.42)
53.24 (41.97–68.89)
41.46 (26.07–49.87)
IL-23
5.255 (2.14–9.004)
52.53 (31.25–60.46)†
4.063 (2.757–8.881)
51.43 (23.9–64.21)‡
IFN-γ
4.648 (3.251–6.484)
4.74 (3.381–5.53)
5 (3.897–5.757)
4.081 (2.899–4.994)†
TNF-α
2.255 (1.575–2.512)
1.499 (1.004–2.158)
2.008 (1.1714–2.672)
1.592 (1.09–2.573)
IL-10
0.3731 (0.2366–0.5108)
0.4265 (0.3394–0.5171)
0.3834 (0.3238–0.4084)
0.3426 (0.277–0.5025)
CCL-11
16.27 (5.453–28.97)
47.69 (39.34–103.8)†
14.56 (4.033–33.35)
75.26 (30.86–110)‡
CCL-24
200.6 (56.02–357.3)
277.3 (133.6–398.4)
184.1 (87.81–756.4)
1,046 (216.5–1,844)†
CXCL-1
1,221 (662.3–2,130)
1,652 (789.4–2,675)
742.9 (446.4–1,258)
1,946 (822–3,988)†
MCP-4
15.66 (8.747–34.57)
17.73 (13.4–33.96)
24.55 (13.62–110.5)
139.6 (25.07–379.3)‡
RANTES
1,511 (1,160–2,803)
1,085 (907.2–1,625)*
1,239 (967–3,031)
692.6 (540–1,337)†
CXCL-2
40.93 (23.91–63.76)
29.25 (25.38–42.5)
46.37 (27.56–64.93)
34.77 (20.09–44.68)
CXCL-8
171.9 (52.49–457.3)
249.5 (137.2–348.6)
67.42 (34.17–183)
152.9 (29.46–662.1)
MPO
41,680 (24,010–52,540)
30,020 (17,200–36,290)
28,410 (18,210–43,070)
14,690 (9,709–40,600)
IL-1α
0.5609 (0.2557–1.548)
0.5974 (0.2205–1.504)
0.48 (0–0.9427)
1.62 (0.5916–3.155)†
IL-1β
3.641 (1.416–7.886)
2.939 (0.8613–6.436)
1.054 (0.1264–2.01)
1.33 (0–3.115)
IL-2Rα
41.61 (29.59–55.64)
58.26 (53.26–71.32)*
35.64 (32–42.62)
84.43 (63.15–89.83)‡
IL-6
4.239 (1.689–12.58)
10.92 (5.554–15.82)
2.338 (0.5062–9.244)
13.29 (5.711–41.43)‡
ICAM-1
139,100 (57,360–165,200)
111,200 (72,000–148,000)
89,140 (76,300–116,700)
97,050 (47,880–146,400)
VCAM-1
5,720 (3,881–7,288)
7,175 (6,149–15,360)*
6,357 (4,683–7,549)
12,030 (8,436–17,590)‡
Values in bold means significant differences compared with those of uncinate mucosa.
UP, uncinate process tissue; NP, nasal polyps; E, eosinophilic; NE, non-eosinophilic; CRSwNP, chronic rhinosinusitis with nasal polyps IL, interleukin; IFN,
interferon; TNF, tumor necrosis factor; CCL, C-C motif chemokine ligand; MCP, monocyte chemoattractant protein; MPO, myeloperoxidase; ICAM, intercellular
adhesion molecule; VCAM, vascular cell adhesion molecule.
*,†,‡The paired comparison of cytokine profiles between UP and NP: (*P < 0.05, †P < 0.01, and ‡P < 0.001; n = 9 in NE-CRSwNP and n = 14 in E-CRSwNP.
Table 5. Paired comparison of remodeling mediators between UP and NP tissues within each endotype of CRSwNP
Parameters (pg/mg)
NE-NP (UP)
NE-CRSwNP (NP)
E-CRSwNP (UP)
E-CRSwNP (NP)
MMP-1
15.66 (8.747–34.57)
175.5 (82.13–251.8)
133.1 (110.3–152.8)
315.1 (186.3–462.6)‡
MMP-2
13,250 (9,540–15,300)
13,360 (12,380–15,800)
13,550 (10,840–15,830)
12,300 (9,641–14,480)
MMP-3
432.8 (248.4–504.7)
606.5 (522.3–860.4)*
395 (363.3–562)
852.1 (670.5–1,179)‡
‡
MMP-9
1,639 (985.8–5,451)
8,857 (5,209–25,420)
761.3 (432.6–2,715)
1,500 (1,166–9,699)*
TIMP-1
10,790 (6,341–11,630)
6,868 (5,891–8,632)
11,530 (10,960–12,160)
9,872 (8,047–12,930)
M1T1
0.0132 (0.008751–0.01483)
0.02511 (0.009179–0.03808)
0.01183 (0.009449–0.01386)
0.02692 (0.01977–0.04809)‡
M2T1
1.308 (1.137–2.049)
2.125 (1.632–2.237)
1.2 (0.9085–1.367)
1.115 (0.8052–1.766)
M3T1
0.04305 (0.03549–0.06414)
0.08649 (0.06457–0.1419)†
0.03433 (0.03048–0.04356)
0.07475 (0.05614–0.158)‡
M9T1
0.2287 (0.1061–0.5736)
1.29 (0.6508–4.026)†
0.0638 (0.03824–0.2365)
0.1572 (0.0813–1.244)*
Values in bold means significant differences compared with those of uncinate mucosa.
UP, uncinate process tissue; NP, nasal polyps; E, eosinophilic; NE, non-eosinophilic; CRSwNP, chronic rhinosinusitis with nasal polyps; MMP, matrix
metalloproteinase; TIMP, tissue inhibitors of metalloproteinase; M1T1, ratio of MMP1 to TIMP1; M2T1, ratio of MMP2 to TIMP1; M3T1, ratio of MMP3 to TIMP1; M9T1,
ratio of MMP1 to TIMP1.
*,†,‡The paired comparison of cytokine profiles between UP and NP: *P < 0.05, †P < 0.01, and ‡P < 0.001; n = 9 in NE-CRSwNP and n = 14 in E-CRSwNP).
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Fig. 1. PCA consists of first and second PCA components of inflammatory mediator levels according to the
different sinonasal tissues. UP, uncinate process tissue; NP, nasal polyps; CRSsNP, chronic rhinosinusitis without
nasal polyps; E, eosinophilic; NE, non-eosinophilic; CRSwNP, chronic rhinosinusitis with nasal polyps.

tissues from NE-CRSwNP and E-CRSwNP groups. However, the expression of CCL-24, MCP-4,
IL-1α, and IL-6 was only increased in NP tissues from patients with E-CRSwNP, but IFN-γ
expression as a Th1 cytokine was decreased in those.

Principal component analysis
To investigate whether the overall profile of multiple mediators could discriminate CRS
subtypes and sinonasal tissue types, we performed the PCA using the interpretation of
multivariate immunoplex data (Fig. 1). The PCA retained 4 components and it presented in
Supplementary Table S3. The first component (PC1) accounted for 23.1% of the variance
in the dataset and its greater discriminators were IL-1β, IFN-γ, IL-6, MMP-9, and IL-1α (in
order). The second component (PC2) accounted for 14.8% of the variance in the dataset
and its greater discriminators included MMP3, CCL-24, VCAM-1, MMP-1, and IL-5 (in
order). Thus, PC1 represented a predominant Th1 or proinflammatory profile, whereas PC2
indicated a relative Th2 profile. In this analysis, we observed that both PC1 and PC2 were
helpful in discriminating between controls and subtypes of CRS. Additionally, the Th2 profile
on PC2 could help distinctly discriminate the different tissues of CRS (UP vs. NP) but were
not helpful in clearly defining for subtypes of NP (NE-CRSwNP-NP vs. E-CRSwNP-NP).

DISCUSSION
In the present study, we compared the profiles of 28 different immunologic markers (T cellassociated cytokine and chemokine, pro-inflammatory mediators, adhesion molecule and
remodeling markers) according to the clinical phenotypes (CRSsNP and CRSwNP) and histologic
subtypes (eosinophilic and non-eosinophilic) of CRSwNP. It has been known that CRSsNP
showed a predominant Th1-skewed response, whereas CRSwNP were classified into 2 subtypes
(E-CRSwNP: Th2-dominant response with eosinophil infiltration; NE-CRSwNP: mixed T cell
subsets with neutrophilic infiltration).10-13 In accordance with the findings of previous studies,
https://e-aair.org
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this study revealed that E-CRSwNP showed higher levels of Th2 cytokines than controls, whereas
NE-CRSwNP significantly related to Th1/Th2/Th17 cytokines compared to controls. Unlike
previous studies, we detected the signature inflammatory markers which have a significantly
increased expression compared with all the other groups. The signature inflammatory markers
are IL-17A, IL-1β (markers for Th17) and MMP-9 (a marker for neutrophil) in patients with
NE-CRSwNP, whereas IL-5, CCL-11, MCP-4 (markers for Th2), and VCAM-1 are the signature
inflammatory markers in patients with E-CRSwNP. Our results also showed the positive
relationship between MMP-9 and neutrophil-associated cytokines, including IL-1α (r = 0.7257,
P = 0.0021), IL-1β (r = 0.6706, P = 0.0058), IL-6 (r = 0.7500, P = 0.0012), CXCL-1 (r = 0.8853,
P < 0.0001), CXCL-2 (r = 0.8000, P = 0.0003) and CXCL-8 (r = 0.6882, P = 0.0042) (data not
shown). Furthermore, we could not detect the significant difference of IFN-γ expression between
control, CRSsNP and CRSwNP (Table 2 and Supplementary Table S1). Several prior studies have
demonstrated the increased levels of IFN-γ expression on CRSsNP.4,15,23-25 However, some recent
studies supported our findings and it also similarly described the IFN-γ expression, which was
not significantly elevated in CRSsNP.26-28
To date, CRSwNP accounts for approximately 20%–30% of all CRS and has been associated
with a more severe clinical disease.29 The concept of this disease has been developed
based on its endotypes, because CRS shows highly heterogeneity which causes different
therapeutic responses.30 However, human studies are very difficult to prove the mechanism
for evolution of NP. This is because CRS patients must be monitored for several years and
immunologic changes must be verified by continuous testing until NP develops. Thus, to
investigate the exact pathophysiology of nasal polypogenesis, the study design should
be followed prospectively, not cross-sectionally. Thus, the present study has an essential
limitation related to study design. To overcome this limitation, in this study, we obtained
UP tissues where NP occurs commonly, as internal controls, then, compared the changes
between UP and NP within the same patient. These comparisons might give us the clue
to what the key protein is while nasal mucosa changes to NP, because the most common
sites of origin for nasal polyposis are where the UP mucosa, the middle concha, and the
ethmoid bulla are in contact with each other.31,32 Based on this paired analysis, we observed
that Th2 mediators may play a role in development of NP, regardless of CRSwNP subtypes.
Additionally, PCA showed there was a partial overlap between NE-CRSwNP and E-CRSwNP
in terms of PC2, discriminators for Th2 mediators, which support the hypothesis that Th2
might be involved in the development of NE-CRSwNP.
Numerous studies have reported that there was a clear association between smoking
history and development of CRS. Generally, cigarette smoke could induce physiologic nasal
responses including increased nasal airway resistance, nasal irritation, nasal congestion, and
rhinorrhea, whereas tobacco smoke extract has been demonstrated to have adverse effects
on sinonasal epithelial mucociliary clearance and innate immune function. However, the
exact effect of smoking on immunologic profile in CRS patients is still unclear. In the present
study, we also investigated the effect of smoking history on immunologic profile according to
the endotypes. We found that the neutrophils-associated mediators such as MPO and MMP-9
were up-regulated in E-CRSwNP with smoking history, whereas E-CRSwNP with no smoking
history was typified as Th2 mediators such as IL-5 and MCP-4. Meanwhile, there was no any
difference in NE-CRSwNP according to the smoking history (Supplementary Table S3).
This study has some limitations. First, regarding study population, asthmatic patients were not
included, and male patients were the majority. It remains unclear whether sex can influence
https://e-aair.org
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levels of cytokines in CRS mucosal tissues. Thus, this issue does not seem to bias our findings.
However, our results might be relevant in a selected phenotype such as non-asthmatics because
this study did not include asthmatic subjects. Secondly, the sample size was relatively small.
Thirdly, the study was designed as a retrospective and cross-sectionally fashion. Therefore,
future studies investigating a large sample and cohort design with a relatively long follow-up
can provide additional evidence for the link between CRSsNP and CRSwNP.
In conclusion, this study shows that there are distinct immunologic profiles among
subtypes of CRS. Specifically, the signature markers of NP tissues from NE-CRSwNP are
IL-17A, IL-1β, and MMP-9 (Th17/neutrophilic related inflammatory markers), whereas IL-5,
CCL-11, MCP-4 and VCAM-1 (Th2 related inflammatory markers) are the signature markers in
NP tissues from E-CRSwNP. Moreover, the increased Th2 immune response was observed by
the paired comparison between NP and UP tissues, regardless of CRSwNP subtypes.

ACKNOWLEDGMENTS
This study was supported by the Basic Science Research Program through the National
Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future
Planning (NRF-2015R1C1A1A01054573 to Dong-Kyu Kim and NRF-2017R1A2B4003445 to
Dae Woo Kim).

SUPPLEMENTARY MATERIALS
Supplementary Table S1
The profile of inflammatory mediators in the subtype of chronic rhinosinusitis
Click here to view

Supplementary Table S2
The profile of remodeling mediators in the subtype of chronic rhinosinusitis
Click here to view

Supplementary Table S3
Coordinates of principal component analysis for the first 4 orthogonally rotated principal
components: inflammatory mediators
Click here to view

REFERENCES
1. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012: European position paper
on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012;50:1-12.
PUBMED | CROSSREF

2. Brandsted R, Sindwani R. Impact of depression on disease-specific symptoms and quality of life in
patients with chronic rhinosinusitis. Am J Rhinol 2007;21:50-4.
PUBMED | CROSSREF

https://e-aair.org

https://doi.org/10.4168/aair.2019.11.2.201

209

Immunological Feature in Chronic Rhinosinusitis

3. Kim H, Han K, Kim SW. Effect of chronic rhinosinusitis with or without nasal polyp on quality of
life in South Korea: 5th Korea National Health and Nutrition Examination Survey Korean. Clin Exp
Otorhinolaryngol 2016;9:150-6.
PUBMED | CROSSREF

4. Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van Cauwenberge P, et al. Differentiation of
chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006;61:1280-9.
PUBMED | CROSSREF

5. Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of chronic rhinosinusitis with and
without nasal polyps. Allergy 2006;61:1275-9.
PUBMED | CROSSREF

6. Van Bruaene N, Pérez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De Ruyck N, et al. T-cell
regulation in chronic paranasal sinus disease. J Allergy Clin Immunol 2008;121:1435-41.
PUBMED | CROSSREF

7. Kim DK, Kang SI, Kong IG, Cho YH, Song SK, Hyun SJ, et al. Two-track medical treatment strategy
according to the clinical scoring system for chronic rhinosinusitis. Allergy Asthma Immunol Res
2018;10:490-502.
PUBMED | CROSSREF

8. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of
chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137:14491456.e4.
PUBMED | CROSSREF

9. Liao B, Liu JX, Li ZY, Zhen Z, Cao PP, Yao Y, et al. Multidimensional endotypes of chronic rhinosinusitis
and their association with treatment outcomes. Allergy 2018;73:1459-69.
PUBMED | CROSSREF

10. Ikeda K, Shiozawa A, Ono N, Kusunoki T, Hirotsu M, Homma H, et al. Subclassification of chronic
rhinosinusitis with nasal polyp based on eosinophil and neutrophil. Laryngoscope 2013;123:E1-9.
PUBMED | CROSSREF

11. Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, et al. Distinct immunopathologic characteristics of
various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol 2009;124:478-84.
PUBMED | CROSSREF

12. Shi LL, Xiong P, Zhang L, Cao PP, Liao B, Lu X, et al. Features of airway remodeling in different types of
Chinese chronic rhinosinusitis are associated with inflammation patterns. Allergy 2013;68:101-9.
PUBMED | CROSSREF

13. Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, DeRuyck N, et al. Different types
of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol
2008;122:961-8.
PUBMED | CROSSREF

14. Kim DK, Jin HR, Eun KM, Mutusamy S, Cho SH, Oh S, et al. Non-eosinophilic nasal polyps shows increased
epithelial proliferation and localized disease pattern in the early stage. PLoS One 2015;10:e0139945.
PUBMED | CROSSREF

15. Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of TH cytokine profiles in patients
with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol
2016;138:1344-53.
PUBMED | CROSSREF

16. Mahdavinia M, Suh LA, Carter RG, Stevens WW, Norton JE, Kato A, et al. Increased noneosinophilic
nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest genetic regulation of
eosinophilia. J Allergy Clin Immunol 2015;135:576-9.
PUBMED | CROSSREF

17. Shin HW, Kim DK, Park MH, Eun KM, Lee M, So D, et al. IL-25 as a novel therapeutic target in nasal
polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2015;135:1476-85.e7.
PUBMED | CROSSREF

18. Kim DK, Jin HR, Eun KM, Mo JH, Cho SH, Oh S, et al. The role of interleukin-33 in chronic rhinosinusitis.
Thorax 2017;72:635-45.
PUBMED | CROSSREF

19. Lam M, Hull L, Imrie A, Snidvongs K, Chin D, Pratt E, et al. Interleukin-25 and interleukin-33 as
mediators of eosinophilic inflammation in chronic rhinosinusitis. Am J Rhinol Allergy 2015;29:175-81.
PUBMED | CROSSREF

20. Jeong WJ, Lee CH, Cho SH, Rhee CS. Eosinophilic allergic polyp: a clinically oriented concept of nasal
polyp. Otolaryngol Head Neck Surg 2011;144:241-6.
PUBMED | CROSSREF

https://e-aair.org

https://doi.org/10.4168/aair.2019.11.2.201

210

Immunological Feature in Chronic Rhinosinusitis

21. Liu X, Dong H, Wang M, Gao Y, Zhang T, Hu G, et al. IL-1α-induced microvascular endothelial cells
promote neutrophil killing by increasing MMP-9 concentration and lysozyme activity. Immunol Res
2016;64:133-42.
PUBMED | CROSSREF

22. Owen CA. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J
Chron Obstruct Pulmon Dis 2008;3:253-68.
PUBMED | CROSSREF

23. Van Bruaene N, Derycke L, Perez-Novo CA, Gevaert P, Holtappels G, De Ruyck N, et al. TGF-beta
signaling and collagen deposition in chronic rhinosinusitis. J Allergy Clin Immunol 2009;124:253-9.
PUBMED | CROSSREF

24. Wang H, Li ZY, Jiang WX, Liao B, Zhai GT, Wang N, et al. The activation and function of IL-36γ in
neutrophilic inflammation in chronic rhinosinusitis. J Allergy Clin Immunol 2018;141:1646-58.
PUBMED | CROSSREF

25. Shi LL, Song J, Xiong P, Cao PP, Liao B, Ma J, et al. Disease-specific T-helper cell polarizing function of
lesional dendritic cells in different types of chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care
Med 2014;190:628-38.
PUBMED | CROSSREF

26. Tan BK, Klingler AI, Poposki JA, Stevens WW, Peters AT, Suh LA, et al. Heterogeneous inflammatory
patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois. J Allergy Clin Immunol
2017;139:699-703.e7.
PUBMED | CROSSREF

27. Stevens WW, Ocampo CJ, Berdnikovs S, Sakashita M, Mahdavinia M, Suh L, et al. Cytokines in chronic
rhinosinusitis. role in eosinophilia and aspirin-exacerbated respiratory disease. Am J Respir Crit Care
Med 2015;192:682-94.
PUBMED | CROSSREF

28. Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE, et al. Thymic stromal
lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin
Immunol 2013;132:593-600.e12.
PUBMED | CROSSREF

29. Tan BK, Chandra RK, Pollak J, Kato A, Conley DB, Peters AT, et al. Incidence and associated premorbid
diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2013;131:1350-60.
PUBMED | CROSSREF

30. Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision
medicine. Allergy Asthma Immunol Res 2017;9:299-306.
PUBMED | CROSSREF

31. Stammberger H. Endoscopic endonasal surgery--concepts in treatment of recurring rhinosinusitis. Part I.
Anatomic and pathophysiologic considerations. Otolaryngol Head Neck Surg 1986;94:143-7.
PUBMED | CROSSREF

32. Stammberger H, Posawetz W. Functional endoscopic sinus surgery. Concept, indications and results of
the Messerklinger technique. Eur Arch Otorhinolaryngol 1990;247:63-76.
PUBMED | CROSSREF

https://e-aair.org

https://doi.org/10.4168/aair.2019.11.2.201

211

